InMed Pharmaceuticals annual stock-based compensation
2020
2021
2022
2023
2024
2025
InMed Pharmaceuticals Stock-Based Compensation Growth & History (INM)
InMed Pharmaceuticals's stock-based compensation was $119,307 for fiscal 2025.
View full InMed Pharmaceuticals company overviewInMed Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $119,307 | −$18,407 | −13.37% |
| 2024 | 2024-06-30 | $137,714 | −$140,441 | −50.49% |
| 2023 | 2023-06-30 | $278,155 | −$419,739 | −60.14% |
| 2022 | 2022-06-30 | $697,894 | $87,701 | +14.37% |
| 2021 | 2021-06-30 | $610,193 | −$384,208 | −38.64% |
| 2020 | 2020-06-30 | $994,401 | — | — |
InMed Pharmaceuticals quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $38,771 | −$1,683 | −4.16% |
| Q2 2026 | 2025-12-31 | $25,264 | $2,105 | +9.09% |
| Q1 2026 | 2025-09-30 | $20,205 | −$8,759 | −30.24% |
| Q4 2025 | 2025-06-30 | $26,730 | −$12,224 | −31.38% |
| Q3 2025 | 2025-03-31 | $40,454 | −$14,851 | −26.85% |
| Q2 2025 | 2024-12-31 | $23,159 | $4,895 | +26.80% |
| Q1 2025 | 2024-09-30 | $28,964 | $3,773 | +14.98% |
| Q4 2024 | 2024-06-30 | $38,954 | −$1,526 | −3.77% |
| Q3 2024 | 2024-03-31 | $55,305 | $4,948 | +9.83% |
| Q2 2024 | 2023-12-31 | $18,264 | −$52,374 | −74.14% |
| Q1 2024 | 2023-09-30 | $25,191 | −$91,489 | −78.41% |
| Q4 2023 | 2023-06-30 | $40,480 | −$136,408 | −77.12% |
| Q3 2023 | 2023-03-31 | $50,357 | −$144,728 | −74.19% |
| Q2 2023 | 2022-12-31 | $70,638 | −$144,141 | −67.11% |
| Q1 2023 | 2022-09-30 | $116,680 | $5,538 | +4.98% |
| Q4 2022 | 2022-06-30 | $176,888 | −$43,962 | −19.91% |
| Q3 2022 | 2022-03-31 | $195,085 | −$12,217 | −5.89% |
| Q2 2022 | 2021-12-31 | $214,779 | $118,145 | +122.26% |
| Q1 2022 | 2021-09-30 | $111,142 | $25,735 | +30.13% |
| Q4 2021 | 2021-06-30 | $220,850 | $64,753 | +41.48% |
| Q3 2021 | 2021-03-31 | $207,302 | $3,433 | +1.68% |
| Q2 2021 | 2020-12-31 | $96,634 | −$187,319 | −65.97% |
| Q1 2021 | 2020-09-30 | $85,407 | −$265,075 | −75.63% |
| Q4 2020 | 2020-06-30 | $156,097 | — | — |
| Q3 2020 | 2020-03-31 | $203,869 | — | — |
| Q2 2020 | 2019-12-31 | $283,953 | — | — |
| Q1 2020 | 2019-09-30 | $350,482 | — | — |
InMed Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, InMed Pharmaceuticals's stock-based compensation decreased from $994,401 to $119,307, a change of −$875,094. The latest reported quarter, Q3 2026, shows $38,771.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review InMed Pharmaceuticals source filings ↗